Enzyme News and Research

RSS

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Promising new strategy for treating human type 2 diabetes

In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.

10 Jun 2011

Promising new strategy for treating human type 2 diabetes

10 Jun 2011

Sulforaphane-rich foods safe and effective for preventing cancer

Sulforaphane, one of the primary phytochemicals in broccoli and other cruciferous vegetables that helps them prevent cancer, has been shown for the first time to selectively target and kill cancer cells while leaving normal prostate cells healthy and unaffected.

10 Jun 2011

Scientists uncover new role for key cancer protein

Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.

10 Jun 2011

Single molecule telomerase activator could extend human cell life indefinitely

When expressed (turned on), the gene (hTERT) located on Chromosome number 5p15.33 activates the enzyme telomerase. Human cells can keep living and dividing indefinitely when telomerase is continually present; i.e. the cells become immortal. Telomerase Activation Sciences, Inc. (T.A. Sciences®) announces TA-65® can extend human cell life indefinitely. TA-65® is a single molecule telomerase activator that turns on the Immortality Gene under controlled laboratory conditions.

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Scientists discover four different bacteria that can live on caffeine

As it turns out, humans aren't the only organisms that turn to caffeine for a pick-me-up. University of Iowa scientists have identified four different bacteria that actually can live on caffeine.

8 Jun 2011

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

8 Jun 2011

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Cyterix Pharmaceutics, Inc. announced today that the company has raised $9.2 million in a Series A financing from The Column Group and SV Life Sciences. Cyterix is developing novel cancer therapeutics based on a prodrug approach that targets extra-hepatic cytochrome P450 enzymes that are over-expressed in many cancers to a high frequency, but not in normal tissues.

7 Jun 2011

Key heart failure therapies could prevent nearly 68,000 deaths each year

A national study has found that nearly 68,000 deaths potentially could be prevented each year by optimally implementing key national guideline-recommended therapies, including critical medications and cardiac devices, for all eligible heart failure patients.

7 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

MMV honors UT Southwestern with Project of the Year for new anti-malarial drug discovery

The discovery of a potential new anti-malarial drug by a UT Southwestern Medical Center-led research team has been awarded Project of the Year by Medicines for Malaria Venture.

7 Jun 2011

Unique clinical trial addresses important questions about treating AIDS-related cancers

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others.

7 Jun 2011

Consumption of high-fat food causes more insulin to be released by the pancreas and leads to obesity

Fat-rich food makes you fat. Behind this simple equation lie complex signalling pathways, through which the neurotransmitters in the brain control the body's energy balance.

7 Jun 2011

SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music

Sound Pharmaceuticals (SPI) will begin recruiting a new clinical trial testing the oral drug SPI-1005 to prevent the hearing loss induced by loud music. Exposure to loud music or noise can induce temporary and permanent auditory threshold shifts (TTS or PTS). In some people, a repeated TTS will ultimately give way to a PTS that is irreversible.

7 Jun 2011

PREMIER Biosoft, Waters partner to advance lipidomics research

Waters Corporation today announced it has entered into a non-exclusive co-marketing and reselling agreement with PREMIER Biosoft International to advance lipidomics research.

7 Jun 2011

Weight loss following bariatric surgery may reduce risk of Alzheimer's

Obesity is a risk factor for Alzheimer's disease, but weight loss due to bariatric surgery may reduce the risk of this common dementia, a new study suggests. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

4 Jun 2011

Enzyme News and Research

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Promising new strategy for treating human type 2 diabetes

Promising new strategy for treating human type 2 diabetes

Sulforaphane-rich foods safe and effective for preventing cancer

Scientists uncover new role for key cancer protein

Single molecule telomerase activator could extend human cell life indefinitely

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Scientists discover four different bacteria that can live on caffeine

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Key heart failure therapies could prevent nearly 68,000 deaths each year

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

MMV honors UT Southwestern with Project of the Year for new anti-malarial drug discovery

Unique clinical trial addresses important questions about treating AIDS-related cancers

Consumption of high-fat food causes more insulin to be released by the pancreas and leads to obesity

SPI to commence enrollment in SPI-1005 clinical trial to prevent hearing loss induced by loud music

PREMIER Biosoft, Waters partner to advance lipidomics research

Weight loss following bariatric surgery may reduce risk of Alzheimer's

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

Biochemical Assays for Efficient Hit Prioritization After Screening eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo